GR3025475T3 - Substituted pyrrolidin-3-yl-alkyl-piperidines useful as tachykinin antagonists - Google Patents

Substituted pyrrolidin-3-yl-alkyl-piperidines useful as tachykinin antagonists

Info

Publication number
GR3025475T3
GR3025475T3 GR970403124T GR970403124T GR3025475T3 GR 3025475 T3 GR3025475 T3 GR 3025475T3 GR 970403124 T GR970403124 T GR 970403124T GR 970403124 T GR970403124 T GR 970403124T GR 3025475 T3 GR3025475 T3 GR 3025475T3
Authority
GR
Greece
Prior art keywords
alkyl
tachykinin antagonists
substituted pyrrolidin
piperidines
useful
Prior art date
Application number
GR970403124T
Other languages
Greek (el)
English (en)
Inventor
Timothy P Burkholder
Tieu-Binh Le
Elizabeth M Kudlacz
George D Maynard
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of GR3025475T3 publication Critical patent/GR3025475T3/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
GR970403124T 1993-05-06 1997-11-26 Substituted pyrrolidin-3-yl-alkyl-piperidines useful as tachykinin antagonists GR3025475T3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5860693A 1993-05-06 1993-05-06
US21848394A 1994-03-28 1994-03-28
US22537194A 1994-04-19 1994-04-19
PCT/US1994/004498 WO1994026735A1 (en) 1993-05-06 1994-04-22 Substituted pyrrolidin-3-yl-alkyl-piperidines useful as tachykinin antagonists

Publications (1)

Publication Number Publication Date
GR3025475T3 true GR3025475T3 (en) 1998-02-27

Family

ID=27369482

Family Applications (1)

Application Number Title Priority Date Filing Date
GR970403124T GR3025475T3 (en) 1993-05-06 1997-11-26 Substituted pyrrolidin-3-yl-alkyl-piperidines useful as tachykinin antagonists

Country Status (18)

Country Link
EP (1) EP0696280B1 (enExample)
JP (1) JP3424174B2 (enExample)
CN (1) CN1081635C (enExample)
AT (1) ATE158580T1 (enExample)
AU (1) AU678023B2 (enExample)
CA (1) CA2160462C (enExample)
DE (1) DE69405862T2 (enExample)
DK (1) DK0696280T3 (enExample)
ES (1) ES2110761T3 (enExample)
FI (1) FI113047B (enExample)
GR (1) GR3025475T3 (enExample)
HU (1) HU224496B1 (enExample)
IL (1) IL109496A (enExample)
MX (1) MX9403386A (enExample)
NO (1) NO309144B1 (enExample)
NZ (1) NZ267209A (enExample)
TW (1) TW281675B (enExample)
WO (1) WO1994026735A1 (enExample)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2717802B1 (fr) * 1994-03-25 1996-06-21 Sanofi Sa Nouveaux composés aromatiques, procédé pour leur préparation et compositions pharmaceutiques en contenant.
DE69508093T2 (de) 1994-08-25 1999-07-15 Merrell Pharmaceuticals Inc., Cincinnati, Ohio Substituierte piperidine für die behandlung von allergischen krankheiten
EP0714891A1 (en) * 1994-11-22 1996-06-05 Eli Lilly And Company Heterocyclic tachykinin receptor antagonists
FR2728165A1 (fr) * 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
FR2728169A1 (fr) * 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
FR2729954B1 (fr) * 1995-01-30 1997-08-01 Sanofi Sa Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
NZ302948A (en) * 1995-03-15 2001-05-25 Aventis Pharma Inc Heterocyclically substituted piperazinone derivatives, preparation and use in pharmaceutical compositions
WO1996032385A1 (en) * 1995-04-13 1996-10-17 Hoechst Marion Roussel, Inc. Novel substituted piperazine derivatives having tachykinin receptor antagonists activity
US5661163A (en) * 1995-06-07 1997-08-26 Merck & Co., Inc. Alpha-1a adrenergic receptor antagonists
FR2738245B1 (fr) * 1995-08-28 1997-11-21 Sanofi Sa Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant
FR2738819B1 (fr) * 1995-09-14 1997-12-05 Sanofi Sa Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant
CA2228572C (en) * 1995-10-10 2003-07-22 Giovanni Piedimonte Nk-1 receptor antagonists for prevention of neurogenic inflammation in gene therapy
US6211199B1 (en) 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
HU224225B1 (hu) 1995-12-01 2005-06-28 Sankyo Co. Ltd. Tachikinin receptor antagonista hatású heterociklusos vegyületek, ezek előállítási eljárása és alkalmazásuk gyógyszerkészítmények előállítására
US6194406B1 (en) 1995-12-20 2001-02-27 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease
US6423704B2 (en) 1995-12-20 2002-07-23 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases
KR20000064487A (ko) * 1995-12-20 2000-11-06 게리 디. 스트리트, 스티븐 엘. 네스비트 알레르기질환의치료에유용한신규의치환된4-(1h-벤즈이미다졸-2-일)1,4디아제판
GB9600235D0 (en) 1996-01-05 1996-03-06 Pfizer Ltd Therapeutic agents
US5922737A (en) * 1996-02-21 1999-07-13 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
US5932571A (en) * 1996-02-21 1999-08-03 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases
US5998439A (en) * 1996-02-21 1999-12-07 Hoescht Marion Roussel, Inc. Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
US5977139A (en) * 1996-12-15 1999-11-02 Hoechst Marion Roussel, Inc. Carboxysubstituted cyclic carboxamide derivatives
PT946548E (pt) * 1996-12-19 2002-06-28 Aventis Pharma Inc Novos derivados de pirrolidino amida substituidos por heterociclos
PL189777B1 (pl) * 1996-12-19 2005-09-30 Aventis Pharma Inc Karboksy-podstawione cykliczne pochodne karboksyamidowe, kompozycja farmaceutyczna zawierająca te związki, zastosowania i sposób wytwarzania tych związków
US5861417A (en) * 1996-12-19 1999-01-19 Hoechst Marion Roussel, Inc. Heterocyclic substituted pyrrolidine amide derivatives
DK0987269T3 (da) 1997-05-30 2003-10-06 Sankyo Co Salte af optisk aktivt sulfoxidderivat
ID29137A (id) * 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
RU2309953C2 (ru) 1999-11-03 2007-11-10 Эймр Текнолоджи, Инк. Арил- и гетероарилзамещенные тетрагидроизохинолины, фармацевтическая композиция и способ лечения на их основе
WO2002004455A2 (en) 2000-07-11 2002-01-17 Albany Molecular Research, Inc 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
ATE402176T1 (de) * 2002-12-13 2008-08-15 Smithkline Beecham Corp Pyrrolidin- und azetidinverbindungen alsccr5- antagonisten
TW200524868A (en) 2003-07-31 2005-08-01 Zeria Pharm Co Ltd Benzylamine derivatives
WO2005037269A1 (ja) * 2003-10-21 2005-04-28 Dainippon Sumitomo Pharma Co., Ltd. 新規ピペリジン誘導体
GB0412865D0 (en) * 2004-06-09 2004-07-14 Glaxo Group Ltd Chemical compounds
US7541357B2 (en) 2004-07-15 2009-06-02 Amr Technology, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
JP2008517916A (ja) * 2004-10-22 2008-05-29 メルク エンド カムパニー インコーポレーテッド Cgrp受容体拮抗薬
US9597314B2 (en) 2005-03-22 2017-03-21 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids for treating premenstrual disorders
EP1888050B1 (en) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer
JP5258561B2 (ja) 2005-07-15 2013-08-07 アルバニー モレキュラー リサーチ, インコーポレイテッド アリール置換およびヘテロアリール置換テトラヒドロベンズアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用
US8048874B2 (en) 2005-07-19 2011-11-01 Azevan Pharmaceuticals, Inc. Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
CN101277960A (zh) 2005-09-29 2008-10-01 默克公司 作为黑皮质素-4受体调节剂的酰化螺哌啶衍生物
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2698157B1 (en) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
EP2109608B1 (en) 2007-01-10 2011-03-23 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
JP2010516731A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド 2−メトキシ−5−(5−トリフルオロメチル−テトラゾール−1−イル)−ベンジル]−(2s−フェニル−ピペリジン−3s−イル)−アミンを含む医薬組成物
JP5319518B2 (ja) 2007-04-02 2013-10-16 Msd株式会社 インドールジオン誘導体
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US8598184B2 (en) 2008-03-03 2013-12-03 Tiger Pharmatech Protein kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
KR20120034644A (ko) 2009-05-12 2012-04-12 알바니 몰레큘라 리써치, 인크. 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
EP2429293B1 (en) 2009-05-12 2014-10-29 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
DK2429296T3 (en) 2009-05-12 2018-03-12 Albany Molecular Res Inc 7 - ([1,2,4,] TRIAZOLO [1,5, -A] PYRIDIN-6-YL) -4- (3,4-DICHLORPHENYL) -1,2,3,4- TETRAHYDROISOQUINOLINE AND USE thereof
BR112012008849A2 (pt) 2009-10-14 2015-09-22 Schering Corp composto, composição farmacêutica, e, uso de um composto
WO2011137012A1 (en) 2010-04-27 2011-11-03 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
ES2662350T3 (es) 2010-07-01 2018-04-06 Azevan Pharmaceuticals, Inc. Procedimientos para el tratamiento del trastorno por estrés postraumático
EP2601293B1 (en) 2010-08-02 2017-12-06 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2013537423A (ja) 2010-08-17 2013-10-03 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸(siNA)を用いたB型肝炎ウイルス(HBV)遺伝子発現のRNA干渉媒介性阻害
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
CN103732592A (zh) 2011-04-21 2014-04-16 默沙东公司 胰岛素样生长因子-1受体抑制剂
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
EP2900241B1 (en) 2012-09-28 2018-08-08 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
AU2013352568B2 (en) 2012-11-28 2019-09-19 Merck Sharp & Dohme Llc Compositions and methods for treating cancer
TW201429969A (zh) 2012-12-20 2014-08-01 Merck Sharp & Dohme 作爲hdm2抑制劑之經取代咪唑吡啶
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
MX382453B (es) 2014-03-28 2025-03-13 Azevan Pharmaceuticals Inc Composiciones y metodos para tratar enfermedades neurodegenerativas
WO2017005583A1 (en) * 2015-07-03 2017-01-12 F. Hoffmann-La Roche Ag Triaza-spirodecanones as ddr1 inhibitors
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
CN111295373B (zh) 2017-09-15 2024-12-10 阿泽凡药物公司 用于治疗脑损伤的组合物和方法
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
BR112021002267A8 (pt) 2018-08-07 2023-02-07 Merck Sharp & Dohme Inibidores de prmt5
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99320A (en) * 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical compositions containing them
FR2676055B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
IL109496A0 (en) 1994-08-26
EP0696280B1 (en) 1997-09-24
HU9503153D0 (en) 1996-01-29
CN1124961A (zh) 1996-06-19
AU678023B2 (en) 1997-05-15
HUT74085A (en) 1996-11-28
NO309144B1 (no) 2000-12-18
CN1081635C (zh) 2002-03-27
ATE158580T1 (de) 1997-10-15
DE69405862T2 (de) 1998-01-15
FI113047B (fi) 2004-02-27
HU224496B1 (hu) 2005-10-28
NO954400L (no) 1996-01-08
AU6942694A (en) 1994-12-12
ES2110761T3 (es) 1998-02-16
NO954400D0 (no) 1995-11-03
DE69405862D1 (de) 1997-10-30
WO1994026735A1 (en) 1994-11-24
EP0696280A1 (en) 1996-02-14
FI955258A0 (fi) 1995-11-02
MX9403386A (es) 1995-01-31
TW281675B (enExample) 1996-07-21
NZ267209A (en) 1997-09-22
FI955258L (fi) 1995-11-30
JPH09500361A (ja) 1997-01-14
DK0696280T3 (da) 1998-01-12
CA2160462A1 (en) 1994-11-24
JP3424174B2 (ja) 2003-07-07
IL109496A (en) 2000-07-26
CA2160462C (en) 1998-12-15

Similar Documents

Publication Publication Date Title
GR3025475T3 (en) Substituted pyrrolidin-3-yl-alkyl-piperidines useful as tachykinin antagonists
ES2160949T3 (es) Derivados de fenilen-sulfonamida sustituidos en meta.
PT894084E (pt) Derivados de acido cinamico e sua utilizacao como antagonistas de integrina
CA2277949A1 (en) Disubstituted bicyclic heterocycles, the preparation and the use thereof as pharmaceutical compositions
CA2239174A1 (en) Novel compounds with analgesic effect
BR9917080A (pt) Composto, composição farmacêutica, uso do composto e método de tratamento ou prevenção de uma disfunção tromboembólica
CA2217006A1 (en) Novel substituted piperazine derivatives having tachykinin receptor antagonists activity
AU2337097A (en) Meta-substituted phenylene derivatives and their use as alphavbeta3 integrin antagonists or inhibitors
CA2337825A1 (en) Disubstituted bicyclic heterocycles, the preparation thereof and their use as pharmaceutical compositions
MY112102A (en) Therapeutic heterocycles.
MX9803954A (es) Derivados de aminoacidos, composiciones farmaceuticas que contienen estos compuestos y procesos para prepararlos.
EP0680328A1 (en) KETOCONAZOLE COMPOSITIONS FOR LOCAL USE.
WO1999026932A8 (en) By amidino group substituted heterocyclic derivatives and their use as anticoagulants
YU30902A (sh) Novi ciklopropani kao cgrp antagonisti, lekovi koji sadrže navedena jedinjenja i postupak za njihovu proizvodnju
CA2237189A1 (en) 3-azetidinylalkylpiperidines or -pyrrolidines as tachykinin antagonists
AU1442297A (en) Piperidone tachykinin antagonists
DK0733051T3 (da) Bicykliske, heterocykliske forbindelser som neurokinin A-antagonister
MY120550A (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, processes for preparing them and their use as pharmaceutical compositions.
MX9708394A (es) Composicion farmaceutica que contiene clorhidrato de tiagabina y el proceso para su preparacion.
MY133169A (en) Substituted heterocyclic benzocycloalkenes and the use thereof as substances having an analgesic effect
GEP20002271B (en) Bicyclic Tachykinins Antagonists, Pharmaceutical Composition on Its Basis and Their Use
AU581856B2 (en) 1-(4'-alkylthiophenyl)-2-amino-1, 3-propanediol N-substituted derivatives
AU2002210537A1 (en) (4-acylaminopiperidin-1-yl) acetamides as neurokinin antagonists
RU94010096A (ru) Производное 1,2,5,6-тетрагидропиридина, способ его получения и фармацевтическая композиция
MX9708021A (es) Fenilamidinas sustituidas, medicamentos que contienen estos compuestos y procedimiento para su preparacion.